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Background: In thymoma patients without myasthenia gravis, it 
is debatable whether thymectomy should be performed in addition 
to thymomectomy, the procedure in which the thymoma alone is 
resected. In this study, we proposed to compare the surgical results in 
early-stage nonmyasthenic thymoma patients who underwent thymo-
mectomy with and without extended thymectomy.
Methods: A total of 95 patients without clinical evidence of preoper-
ative myasthenia gravis, who underwent surgery for early-stage thy-
moma (stages I and II), were selected for the study. Thymomectomy 
with extended thymectomy was performed through median sternot-
omy on 42 patients, whereas thymomectomy without thymectomy 
was carried out through video-assisted thoracoscopic surgery (VATS) 
or thoracotomy in 53 patients. Outcomes and surgical complications 
were compared between the two patient groups.
Results: The median duration of the follow-up was 57 months 
(6–121 months). Three patients, one in the thymomectomy group 
(1.9%) and two in the thymomectomy with thymectomy group 
(4.5%), developed tumor recurrences. Tumor recurrence rates 
between the two groups were not significantly different. During 
the follow-up period, we did not document the development of 
postoperative myasthenia gravis in any of the patients enrolled. 
Postoperative opioid use, the number of days of drainage, and hos-
pitalization length were lower in patients undergoing thymomec-
tomy through thoracotomy or VATS.
Conclusions: In early-stage nonmyasthenic thymoma patients, thy-
momectomy without thymectomy through thoracotomy or VATS 
was associated with lower morbidity and shorter hospitalization, 
than thymomectomy with extended thymectomy. Postoperative 
myasthenia gravis did not develop in any of the patients enrolled 
in our study during the 57-month median follow-up period. Overall 
tumor recurrence rates were not significantly different between 
these two patient groups. On the basis of our results, we conclude 
that thymomectomy without thymectomy through thoracotomy or 
VATS is justified for early-stage nonmyasthenic thymoma patients, 
and longer follow-up is needed to investigate the necessity of thy-
mectomy in this group.
Key Words: Thymoma, Thymomectomy, Extended thymectomy, 
Video-assisted thoracoscopic surgery.
(J Thorac Oncol. 2013;8: 952-958)
Thymoma, the most common anterior mediastinal tumor in the adult population, has an indolent growth pattern, but 
presents the potential for malignant transformation with local 
invasion and pleural dissemination.1,2 In the United States, 
the overall incidence of thymoma is 0.13 in 100,000 persons.3 
It was reported that, at the time of diagnosis approximately 
50% of the thymomas were encapsulated without invading 
adjacent organs, which may correspond to Masaoka stages 
I and II.4,5 The mainstay treatment for thymoma is surgery.6,7 
Generally, as Toker et al.6 recommended, median sternotomy, 
with an en bloc removal of the entire thymus and mediastinal 
fat bilaterally between the phrenic nerves and from the 
diaphragm to the innominate vein, should be performed 
to decrease tumor recurrences. Median sternotomy for 
thymectomy, even though not common, accounts for serious 
complications, including mediastinitis and osteomyelitis.8 
Recently, video-assisted thoracoscopic surgery (VATS), with 
all the technological advances, or robotic-assisted resection 
of thymoma and thymectomy have been advocated at certain 
institutes.9–12 Myasthenia gravis is present in a significant 
proportion of patients with thymoma. In these patients, 
thymectomy in addition to the complete resection of thymoma 
is always indicated. However, in cases of thymoma without 
myasthenia gravis, whether thymectomy should be performed 
in addition to thymoma resection remains debatable.13,14 
Only a few cases of postoperative myasthenia gravis, after 
thymoma removal in previously nonmyasthenic patients, 
were reported in the literature.15–17 The aim of this study was 
to compare the surgical results of thymomectomy through 
thoracotomy or VATS with thymomectomy with extended 
thymectomy through median sternotomy in nonmyasthenic 
patients with stage I and II thymomas, and to discuss the 
efficacy of thymectomy in these patients.
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PATIENTS AND METHODS
Patient Characteristics
A total of 95 patients without clinical evidence of pre-
operative myasthenia gravis, who underwent surgery for early-
stage thymoma (stages I and II) in Taipei Veterans General 
Hospital (Taiwan) between January 2002 and August 2011, 
were selected for the study. Our Institutional Review Board 
approved this study and granted an exemption from informed 
consent (201208010BC). The process of patient selection is 
shown in Figure 1. Only patients with stage I or II thymoma 
were selected for analysis. Patients having incomplete resec-
tion were inevitably stage III or IV after surgery, and were 
thus, excluded from the study. From 16 nonmyasthenic 
patients with stage III or IV thymoma, 10 patients underwent 
median sternotomy for thymomectomy (thymomectomy and 
thymectomy) and six patients underwent thoracotomy for thy-
momectomy. In these 16 patients, four patients had incomplete 
resection (R1 or R2 resection), including two patients receiv-
ing thymectomy, and two patients thymomectomy only. In our 
institution, biopsy was not routinely performed preoperatively 
for anterior mediastinal tumors, unless they were considered to 
be nonresectable. All patients in our study underwent imaging 
studies, including chest computed tomography or magnetic 
resonance scans, before surgery. In our institution, positron 
emission tomography scans were not routinely performed on 
patients with thymomas. The imaging findings for early thy-
momas usually showed sharply demarcated, elongated, round, 
or lobulated tumors. Most often, tumor growth occurs asym-
metrically to one side of the mediastinum and they appear 
homogeneous in attenuation with or without contrast injec-
tion. Calcification may occur in the capsule or within the 
tumors. The clinical data for these 95 patients, including sex, 
age, surgical procedures, tumor size, pathological diagnosis, 
adjuvant therapy, tumor recurrence, postoperative develop-
ment of myasthenia gravis, surgical complications, and out-
come were retrospectively reviewed. For patients with tumors 
located superiorly in the mediastinum near the innominate 
vein, median sternotomy was usually performed. For patients 
with well-defined tumors located laterally and inferiorly in the 
mediastinum, thoracotomy or VATS was usually preferred. 
Among these 95 patients, tumor removal (thymomectomy), in 
FIGURE 1.  Patient selection.
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addition to extended thymectomy through median sternotomy, 
was performed on 42 patients, whereas thymomectomy with-
out thymectomy was carried out through VATS or thoracotomy 
on 53 patients. VATS was performed through a thoracoscopi-
cally guided anterior minithoracotomy with a 2- to 3-cm 
working port. For patients with thoracotomy or VATS, some 
thymic tissue and perithymic fat were dissected to avoid injury 
from the tumor capsule. All study participants had complete 
resection of the tumors (R0 resection). In patients with thy-
mectomy, surgery was performed through median sternotomy. 
After the mediastinum was entered, the pleura was opened on 
both sides. The thymus, along with the tumor and the adja-
cent pericardial fat, was freed from the pericardium and the 
mediastinal pleura. The cervical extension of each lobe was 
easily removed with the body of the gland by gentle traction. 
The phrenic nerves were carefully identified and preserved 
throughout the procedure. For tumor removal by thoracotomy 
or VATS without thymectomy, patients were placed in right or 
left lateral position. Tumors, along with some thymic tissue or 
perithymic fat, were carefully removed with a safe margin. The 
phrenic nerve was properly identified and protected during the 
procedure. The performance status of these patients was good. 
All patients in the study were Eastern Cooperative Oncology 
Group grade 0, which means that they were fully active and 
able to carry on with all activities that they performed before, 
without any restrictions. Four surgeons, who are among the 
authors, performed the operations during the study period. 
Chest tubes were usually removed when the pleural effusions 
became serosanguinous, and the drainage volume was less 
than 150 ml per day, without air leaks. Follow-up was per-
formed for all patients at outpatient clinics on a regular basis, 
every 6 months for the first 5 years postsurgery, and annu-
ally after that. Chest computed scans were used to evaluate 
tumor recurrences. Adjuvant radiotherapy was given to some 
patients when tumors were of more aggressive World Health 
Organization (WHO) histological types, including B2 and B3. 
Surgical complications and outcomes were compared between 
these two patient groups.
Statistical Analysis
SPSS version 13.0 statistical software was used for 
data analysis (SPSS Inc., Chicago, IL). Continuous data were 
expressed as mean ± SD. Continuous variables were ana-
lyzed by the independent t test or the Mann–Witney U test. To 
compare the frequencies between the two groups, the χ2 tests 
were applied for the univariate analysis. Disease-free survival 
curves were estimated by the Kaplan–Meier method and com-
pared by the log-rank test. A p value of less than 0.05 was 
considered statistically significant.
RESULTS
Patient characteristics are summarized in Table 1. All 
95 patients underwent complete resection of the thymoma. Of 
these, 34 had Masaoka stage I, and 61 had stage II thymoma, 
including 17 patients with stage IIA and 44 patients with 
stage IIB. Postoperative adjuvant therapy was administered 
to 18 of 53 patients undergoing thymomectomy, and to 16 
of 42 patients undergoing thymomectomy with thymectomy. 
Lymph node dissection was not performed routinely on these 
patients. In the thymomectomy group, lymph node sampling 
was performed for five patients only. Of these, one lymph 
node was removed in three patients, and four and seven lymph 
nodes were removed in one patient each, respectively. In the 
thymomectomy with thymectomy group, seven patients had 
lymph nodes sampled during operation. The number of lymph 
nodes removed was one in four patients, and two, three, and 
nine in one patient each, respectively. No tumor involvement 
was found in the lymph nodes removed in these patients. 
Between groups, the study variables, including sex, tumor 
behavior, and tumor size, were not statistically different. 
The only difference between the groups was age. Patients 
undergoing thymomectomy without thymectomy were older 
than those who underwent only thymectomy. An analysis of age 
and tumor characteristics was further performed and showed 
no statistical differences in these patients (Table 2). Surgical 
outcomes are shown in Table 3. The duration of surgery was 
significantly shorter in patients undergoing thymomectomy 
than in patients undergoing thymomectomy with thymectomy. 
Blood loss during surgery was also lower in patients undergoing 
thymomectomy. In addition, postoperative opioid use, the 
number of days of drainage, and the length of hospital stay 






(n = 42) (%)
Thymomectomy  
without Thymectomy 
(n = 53)(%) p
Sex male/female 19/23 23/30 0.858
Age (yr, mean ± SD) 48.8 ± 11.4 55.5 ± 12.3 0.010
Masaoka stage 0.128
 I 11 (26.2) 23 (43.3)
 IIA 6 (14.3) 11(20.8)
 IIB 25 (59.5) 19 (35.9)
WHO histological  
types
0.106
 A 2 (4.8) 8 (15.1)
 AB 21 (50.0) 17 (32.1)
 B1 13 (31.0) 11 (20.8)
 B2 3 (7.1) 10 (18.8)








 VATS — 22
Tumor size (cm,  
mean ± SD)
6.6 ± 2.1 6.2 ± 3.0 0.620
Adjuvant therapy 0.478
 Radiation 16 15
 Chemotherapy — 1
VATS, video-assisted thoracoscopic surgery; WHO, World Health Organization; SD, 
standard deviation.
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had major bleeding because of innominate vein injury during 
surgery. The approach taken for this patient was performing 
VATS from the left side. The procedure was then converted to 
lateral thoracotomy to check the bleeding. In the 31 patients 
with thoracotomy, surgical approach was from the right side 
in 14 patients and from the left side in 17 patients. In the 22 
patients with VATS, the approach was from the right side in 13 
patients and from the left side in nine patients. Postoperative 
complications occurred in two patients in the thymomectomy 
group, and included phrenic-nerve injury and chylothorax. 
Sternal osteomyelitis occurred in one patient undergoing 
thymomectomy with thymectomy through sternotomy. No 
surgery-related mortality occurred in any of the patients. The 
case number of patients undergoing thymoma removal, with 
and without thymectomy before and after 2007, is shown in 
Figure 2. The percentage of patients without thymectomy 
increased after 2007. The median duration of the follow-up 
was 57 months (6–121 months) for all patients, 62 months for 
patients with thymectomy, and 55 months for patients without 
thymectomy. No patients were lost during follow-up in the 
study. No myasthenia gravis development was seen during 
the postoperative follow-up in any of the patients included. 
Three patients, one in the thymomectomy group (1.9%) and 
two in the thymomectomy with thymectomy group (4.5%), 
developed tumor recurrences. Their relapse patterns are listed 
in Table 4. In the group that underwent thymomectomy, the 
tumor recurred in one patient. The relapse pattern in this 
patient was pleural seeding, indicating regional recurrence 
within the intrathorax and not contiguous with the thymus 
or the thymoma. In the group that underwent thymectomy, 
two patients had tumor recurrences. Their relapse patterns 
were pleural seeding and lung metastasis, indicating distant 
metastasis to the lung parenchyma. All these three patients 
received adjuvant radiotherapy or chemotherapy and were 
still alive, despite the tumor recurrences. The freedom-from-
recurrence curve with error bars for the 5-year timepoint is 
shown in Figure 3. The vertical bars indicate 95% confidence 
intervals for the thymectomy (0.88,1) and thymomectomy 
(0.79,1) groups. The 5-year freedom-from-recurrence rate 
was 96.8%. Surgical approach, age, sex, tumor stage, tumor 
size, and WHO classification were not statistically different 
between patients with and without tumor recurrence. The age 
of the three patients with tumor recurrences was 42, 45, and 
48 years, respectively. All these three patients were Masaoka 
stage IIB and WHO histological types B1 to B3, respectively. 
The tumor recurrence rate was 4.9% in patients with stage 
II disease. The time from surgery to recurrences in these 
three patients was 7, 23, and 60 months, respectively. Two of 
the three patients received postoperative adjuvant radiation 
therapy after the initial thymoma resection. After the tumor 
recurrences occurred, all three patients underwent surgery 
and further chemoirradiation. All patients in this study are 
still alive, including the patients with disease recurrences. The 
overall survival rate is 100%.
DISCUSSION
Surgery remains the mainstay treatment for thymoma. 
Most surgeons recommend additional thymectomy, 
irrespective of the presence of myasthenia gravis.1–6,13,14 
Murakawa et al.13 reported their experience on the surgical 
treatment of thymomas. In their series, the authors mentioned 
that before 1976, patients with thymoma underwent 
thymomectomy without extended thymectomy. In these 
patients with stage I thymoma, tumor recurrence rates were 
14.8% (4 of 27 patients). The authors concluded that stage I 
thymoma can be completely cured by extended thymectomy 
with thymomectomy through median sternotomy. The article 
did not mention the incidence of postoperative myasthenia 
gravis. Our study represents the largest series in the literature 
to present the surgical outcomes in early-stage nonmyasthenic 
thymoma patients. In contrast to the findings of Murakawa 
et al., tumor recurrences in our series occurred in only one 
of 53 patients (1.9%) undergoing thymomectomy without 
thymectomy. We also found that tumor removal without 
extended thymectomy, through thoracotomy or VATS, 
TABLE 2.  Comparison between Age and Tumor 
Characteristics in 95 Patients
Variables Number (%) Age (yr, Mean ± SD) p
Masaoka stage 0.324
 Stage I 34 (35.8) 51.8 ± 13.7
 Stage II 61 (64.2) 53.0 ± 11.6
WHO histological type 0.291
 A, AB 48 (50.5) 54.4 ± 12.3
 B1, B2 37 (38.9) 50.7 ± 11.5
 B3 10 (10.6) 49.2 ± 16.4





with Thymectomy  
(n = 42)
Thymomectomy  
without Thymectomy  
(n = 53) p
Duration of surgery 
(min)
217.1 ± 54.1 130.7 ± 51.8 <0.001
Blood loss (ml) 309.6 ± 197.3 135.8 ± 410.9a 0.013
Extubation (days) 1.7 ± 1.0 0.6 ± 0.8 <0.001
ICU stay (days) 2.3 ± 1.7 1.3 ± 0.8 0.001
Postoperative  
drainage (days)
7.6 ± 1.9 6.0 ± 2.8 0.001
Postoperative opioid  
use (days)
5.3 ± 2.1 4.8 ± 1.5 0.073
Postoperative hospital  
stay (days)
8.1 ± 2.3 6.5 ± 3.0 0.010






Tumor recurrence 2 1 0.404
ICU, intensive care unit.
aBlood loss of 3000 ml in one case because of innominate vein injury. 
bOsteomyelitis of sternum. 
cPhrenic-nerve injury and chylothorax, respectively.
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presents several advantages, including decreased blood loss, 
earlier extubation and chest tube removal, shorter stay in the 
intensive care unit, and shorter postoperative hospitalization.
The incidence of postoperative myasthenia gravis 
developing in nonmyasthenic thymoma patients after 
resection is not clear, and it is currently not known whether 
thymectomy plays a role in preventing postoperative 
myasthenia gravis development. Only sporadic cases of 
postoperative myasthenia gravis have been reported in the 
literature.15–18 Terauchi et al.15 reported an asymptomatic 
thymoma patient who developed myasthenia gravis and lung 
metastasis 12 years after undergoing thymoma resection. 
This patient had WHO B1 and stage I thymoma. In 2005, 
Kondo et al.14 examined 1089 thymoma patients from 
115 institutes in Japan, and found that myasthenia gravis 
developed postoperatively in eight of 827 participants (0.9%) 
who did not have preoperative myasthenia gravis. All these 
eight patients underwent extended thymectomy in addition 
to tumor resection, and no tumor recurrences were noted in 
them. In their series, none of the patients undergoing tumor 
resection alone developed postoperative myasthenia gravis. 
The authors concluded that thymus resection does not prevent 
postoperative myasthenia gravis. In 2008, Nakajima and 
colleagues19 presented their results about post-thymectomy 
myasthenia gravis. Fifty-five asymptomatic patients with 
thymoma undergoing thymectomy were enrolled. Five of 
them developed post-thymectomy myasthenia gravis 3 to 46 
months after thymectomy, and only one patient presented a 
tumor recurrence during the follow-up period. Recently, Sun 
et al.17 reported that six of 125 thymoma patients without 
preoperative myasthenia gravis developed postoperative 
myasthenia gravis. All these six patients underwent 
thymectomy, including resection of the thymoma and of the 
thymus gland. None of the patients undergoing thymoma 
resection alone developed postoperative myasthenia gravis. 
It is of interest that all patients who developed postoperative 
myasthenia gravis in these reports underwent thymectomy 
in addition to thymomectomy. In our series, none of the 
95 patients selected in the study had myasthenia gravis 
preoperatively, and none of them developed it postoperatively. 
The reason why certain asymptomatic patients undergoing 
thymectomy for thymomas still developed myasthenia gravis 
postoperatively is unknown. Further investigations are 
mandatory to elucidate whether thymectomy is necessary in 
early-stage nonmyasthenic thymoma patients.
Tumor recurrence after surgery in thymoma patients 
is related to the tumor stage and WHO histological type, 
the completeness of its surgical removal, and the type of 
treatment.20–22 Kondo et al.23 reported tumor recurrence 
rates of 0.9%, 4.1%, 28.4%, 34.3%, and 51% for stage I, 
II, III, and IV tumors and thymic carcinoma, respectively.14 
Haniuda et al.21 found recurrence rates ranging between 
5% and 50%, depending on the initial staging of the dis-






Case Age (yr) Sex Masaoka Stage WHO Type Surgery Recurrence Site
1 42 Female IIB B1 Thymomectomy Pleural seeding
2 45 Female IIB B3 Extended thymectomy RUL metastasis with pleural seeding
3 48 Female IIB B2 Extended thymectomy LUL metastasis with pleural seeding
WHO, World Health Organization; LUL, left upper lobe; RUL, right upper lobe.
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228 thymoma patients that the long-term outcome is related 
to tumor stage, WHO histology, and the type of treatment. 
Chang et al.20 reviewed 76 patients with stage II or III thy-
momas and found that Masaoka staging and adjuvant radia-
tion were related to disease-free survival in completely 
resected tumors. Recently, Sakamoto et al.24 reported the 
results of extended thymectomy through median sternotomy 
for 162 thymoma patients, and found that type B3 is a poor 
prognostic factor for survival. In our study, three patients 
developed tumor recurrences. Two recurrences occurred 
in patients with extended thymectomy and one in a patient 
with thymomectomy through thoracotomy. No tumor recur-
rences were recorded in patients undergoing thymomectomy 
with VATS. These three patients were at Masaoka stage IIB 
and had tumors with WHO histological types of B1 to B3, 
respectively. The overall tumor recurrence rate in the study 
was only 3.16%. Two of these three patients received post-
operative adjuvant radiotherapy after the initial surgical 
intervention. In the study, the percentage of patients without 
thymectomy increased after 2007. Even though some tem-
poral bias existed regarding surgical approaches, only one 
patient had tumor recurrence in a 21-patient series undergo-
ing thymomectomy without thymectomy before 2007, and 
none of them developed myasthenia gravis. The mean fol-
low-up duration in these patients was 82.9 months.
There are several limitations to this study. First, this 
is a nonrandomized retrospective study with a 57-month 
median follow-up, and with the longest follow-up duration 
of 121 months. Because thymoma is an indolent tumor, 
a longer follow-up may be needed. Second, the surgical 
procedures were performed according to the tumor location 
and the surgeon’s preferences, and some selection bias could 
exist. Third, because this study consisted of only early-stage 
nonmyasthenic thymoma patients from a single institute, 
the analysis may not be sufficient to reach an appropriate 
conclusion. A larger patient cohort and case-match study, or 
a prospective controlled study may be needed to solve this 
controversial issue.
In summary, for early-stage nonmyasthenic thymoma 
patients, thymomectomy without thymectomy, through tho-
racotomy or VATS, was associated with less morbidity and 
shorter hospitalization than thymomectomy with extended 
thymectomy. We did not notice postoperative myasthenia gra-
vis in any of the study patients during the 57-month median 
follow-up. The overall tumor recurrence rate, which was 
only 3.16%, was not significantly different between the two 
patient groups. We conclude that thymomectomy without thy-
mectomy, through thoracotomy or VATS, is justified in early-
stage nonmyasthenic thymoma patients. Longer follow-up is 
required to investigate the necessity of thymectomy in early-
stage nonmyasthenic thymoma patients.
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